Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.
about
Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesCefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.Expert systems in clinical microbiology.Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.Setting and revising antibacterial susceptibility breakpoints.Zinc Finger Nuclease: A New Approach to Overcome Beta-Lactam Antibiotic Resistance.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceOptimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsPhase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.Clinical significance of extended-spectrum beta-lactamases.Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?Antimicrobial resistance in internal medicine wards.Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase.Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic modelMutagenesis of the CTX-M-type ESBL-is MIC-guided treatment according to the new EUCAST recommendations a safe approach?Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods.Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012Treatment of extended-spectrum Beta-lactamase enterobacteriaceae with cefepime: the dose matters, too.Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella speciesDetection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.Superiority of ceftriaxon to cefazolin in a rat model of obstructive jaundice: an experimental study.Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.High rates of susceptibility to ceftazidime among globally prevalent CTX-M-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.The clinical and public health challenge of Gram-negative resistance in Australasia.Evaluation of detection of extended-spectrum beta-lactamases among Escherichia coli and Klebsiella spp. isolates by VITEK 2 AST-N029 compared to the agar dilution and disk diffusion methods.Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.Stepping Off the Resistance Treadmill.Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing
P2860
Q28249617-0DED1531-11A2-46A8-AF93-6BB0E3BFA153Q34244192-F73EF0C0-252C-4229-8CA0-E36FD65C8CFAQ35090146-6B40F422-8864-46F9-9D30-7A6890C7FDBFQ35840852-5DB1409D-4CAD-4DB5-85D5-8745C4FC853BQ35913176-00DE2C36-7ACF-4E7D-BFFF-E3BC12312C07Q35995546-3A9D5B76-4790-4B5A-921C-D7DF9B9C57F6Q36329228-7402DBFF-6365-4701-B474-74C3B15EFB17Q36364100-34E7FF84-E6FE-4B40-AE91-582C08E991A5Q37055016-11D85DCF-E0CB-4C6B-85A6-F8D728F61627Q37287753-BD7C4ACE-E092-4BF9-9A6F-D2930374121FQ37291354-64FF894B-925C-4C4E-9012-8BAE2F09C9E8Q37998436-5D9AE064-104B-4E69-A82E-D7BD865DC8B5Q38052855-F049A662-58A1-429D-8262-52F366152470Q38075482-B7238C7D-3C28-414E-907D-B789787771D5Q38165138-588FE9C5-DF76-41AE-B32D-6A918807835BQ38528292-7F2D31CD-A55D-4192-966D-253554D8F1F8Q38536299-AD1C5718-E809-44BE-8ECB-854A56456768Q38595451-3F527D60-6E84-4E7C-B4DE-A3208E24B89DQ38741453-7E0A24BF-22ED-499E-BE73-C92047B6DE04Q38792841-3BE3D27B-D41C-4268-BAD4-FB737CE934E8Q39147849-C459B32B-55D0-48CC-8413-23DBE17CF776Q40303951-43B6909B-0A87-43A4-93B5-E75551DD4B97Q40573594-A9C74F39-52AC-4C05-A430-470E7E1FCA03Q41077573-4C798C8E-4CBE-49A4-B203-54DF0433021AQ41163382-B1F78BD0-B301-4B37-9790-DC74B8562D38Q41429331-07F1F944-E2BD-4E07-8E86-A32963860B05Q42000603-04C7D04A-D08E-492C-86C8-F304EEA4AFFAQ42561118-F21C1E03-E4BA-492A-A8CF-0D2107F09E9AQ42566982-E823FDFE-05BD-457D-A9D7-D9F4276FC513Q42799124-FC7E1514-06F7-480F-BBF1-FF374EAC21D9Q46641706-14142F47-E0F0-42FE-A7F1-26EAB0DC891CQ46857071-BA52422C-EF49-4C67-BF29-BACC37D76406Q51010477-AE3F8A90-8407-4CA6-A55A-AC8B8EAB1259Q51330567-1A923B41-71E0-4F12-BC26-FDBB7180EBD1Q51700680-DC7BF016-2A82-409E-884C-FAA127A7A073Q52591821-B06E0F49-C124-4AC4-95BB-C89D85CF9CDAQ53311081-163C6716-211A-4A29-ACCC-8755FAB9ABCBQ55514103-835175FB-C468-438D-ADE6-F69A088C7DF9Q58088798-E2972F4C-0E2D-4202-828E-6188B583EE51
P2860
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Treatment of infections with E ...... harmacodynamic considerations.
@ast
Treatment of infections with E ...... harmacodynamic considerations.
@en
type
label
Treatment of infections with E ...... harmacodynamic considerations.
@ast
Treatment of infections with E ...... harmacodynamic considerations.
@en
prefLabel
Treatment of infections with E ...... harmacodynamic considerations.
@ast
Treatment of infections with E ...... harmacodynamic considerations.
@en
P1476
Treatment of infections with E ...... pharmacodynamic considerations
@en
P2093
P356
10.1111/J.1469-0691.2005.01265.X
P478
11 Suppl 6
P50
P577
2005-11-01T00:00:00Z